Start Your Risk-Free Subscription

Login

The Daily Biopharmaceutical News Source

Advanced Search

Clinuvel Filing for Scenesse in EU on Phase III Data in EPP

By Cormac Sheridan
BioWorld International Correspondent

Wednesday, December 21, 2011

Clinuvel Pharmaceuticals Ltd. plans to complete a European regulatory filing for its lead drug Scenesse (afamelanotide) in the coming weeks, following a Phase III trial in patients with erythropoietic protoporphyria (EPP), which met its primary endpoint.

To continue reading subscribe now to BioWorld International

Learn More about BioWorld International

Already a subscriber? Sign In or Buy now to activate your subscription

»

Login or register to post comments

Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST

BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA

Part of Thompson Media Group LLC
Thompson.com | Sheshunoff.com | ASPratt.com | AHCMedia.com | BioWorld.com | CMEweb.com | ThePerformanceInstitute.org | ASMIweb.com

Editorial Guidelines

For Site License Discounts, please contact Customer Service at (800) 477-6307 or customerservice@bioworld.com.